ArticlePloS one2025
GalNAc in vaginal secretions: a potential non-invasive risk indicator associated with the risk of premature rupture of membranes.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature rupture of membranes (PROM) is a major contributor to preterm birth and neonatal morbidity. Current diagnostics are predominantly reactive and detect rupture only after it occurs. In a clinical cohort of 60 pregnant women (20 with PROM, 40 gestational controls at 31-36 weeks), we developed and validated a colorimetric assay for N-acetyl-D-galactosamine (GalNAc) in vaginal secretions. GalNAc levels were significantly lower in the PROM group than in controls, and the assay exhibited linearity, precision, stability, and resistance to interference. Receiver-operating characteristic analysis yielded an AUC of 0.821 (95% CI 0.80-0.97). These data support reduced vaginal GalNAc as a potential non-invasive risk indicator of PROM. While longitudinal validation is required, this approach may enable early risk stratification to guide preventive interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.